HC Wainwright reissued their buy rating on shares of Dynavax Technologies (NASDAQ:DVAX) in a research report sent to investors on Thursday, AnalystRatings.com reports.
DVAX has been the topic of a number of other research reports. BidaskClub upgraded shares of Dynavax Technologies from a hold rating to a buy rating in a report on Thursday, October 24th. Cantor Fitzgerald upgraded shares of Dynavax Technologies from a neutral rating to an overweight rating and set a $20.00 price target on the stock in a report on Wednesday, July 10th. William Blair reiterated a buy rating on shares of Dynavax Technologies in a report on Friday, August 16th. Zacks Investment Research lowered shares of Dynavax Technologies from a buy rating to a hold rating in a report on Tuesday, October 15th. Finally, ValuEngine upgraded shares of Dynavax Technologies from a sell rating to a hold rating in a report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $12.63.
Dynavax Technologies stock traded up $0.19 during mid-day trading on Thursday, reaching $5.26. The company had a trading volume of 1,426,300 shares, compared to its average volume of 1,330,133. The company has a market capitalization of $349.23 million, a P/E ratio of -2.06 and a beta of 0.50. The stock’s 50-day simple moving average is $4.39 and its 200-day simple moving average is $4.54. Dynavax Technologies has a 1 year low of $2.60 and a 1 year high of $12.77. The company has a debt-to-equity ratio of 19.95, a current ratio of 4.30 and a quick ratio of 3.47.
Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.10). The company had revenue of $10.58 million during the quarter, compared to analyst estimates of $10.31 million. Dynavax Technologies had a negative net margin of 781.10% and a negative return on equity of 304.71%. The firm’s revenue for the quarter was up 624.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.65) EPS. On average, equities analysts forecast that Dynavax Technologies will post -1.93 EPS for the current fiscal year.
In other Dynavax Technologies news, Director Francis Cano bought 16,667 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were acquired at an average price of $3.00 per share, with a total value of $50,001.00. Following the purchase, the director now owns 118,484 shares in the company, valued at approximately $355,452. The purchase was disclosed in a document filed with the SEC, which is available through this link. 4.90% of the stock is owned by company insiders.
Several hedge funds have recently modified their holdings of the company. M&T Bank Corp raised its stake in shares of Dynavax Technologies by 29.5% in the 2nd quarter. M&T Bank Corp now owns 13,685 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 3,116 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Dynavax Technologies by 95.0% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,984 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 3,402 shares during the period. Commonwealth Equity Services LLC raised its stake in shares of Dynavax Technologies by 15.1% in the 3rd quarter. Commonwealth Equity Services LLC now owns 30,034 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 3,950 shares during the period. Gables Capital Management Inc. raised its stake in shares of Dynavax Technologies by 6.7% in the 3rd quarter. Gables Capital Management Inc. now owns 64,050 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 4,000 shares during the period. Finally, Bank of Montreal Can raised its stake in shares of Dynavax Technologies by 148.4% in the 2nd quarter. Bank of Montreal Can now owns 7,440 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 4,445 shares during the period. 83.08% of the stock is currently owned by institutional investors and hedge funds.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Featured Article: What does an outperform rating mean?
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.